Skip to Content

Exact Sciences Corp EXAS

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Exact Starts Year On Right Track; Cologuard Driving Near-Term Growth With Pipeline Projects Underway

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

Exact Sciences had a pretty good start to the year and exceeded consensus estimates aggregated by Visible Alpha (12% beat on revenue and lower losses than anticipated), though reported figures were a tad below our expectations. We are maintaining our $76 fair value estimate and no-moat rating. While the shares remain overvalued, the stock has fallen over 25% from all-time highs, and we think investors should be alert for a potential entry point if the negative momentum continues.

Read Full Analysis

Company Profile

Business Description

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.

Contact
441 Charmany Drive
Madison, WI, 53719
T +1 608 284-5700
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2020
Stock Type Speculative Growth
Employees 5,000